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Stem cell therapies can promote neural repair and regeneration, yet controversy regard-
ing optimal cell source and mechanism of action has slowed clinical translation, poten-
tially due to undefined cellular heterogeneity. Single-cell resolution is needed to identify 
clinically relevant subpopulations with the highest therapeutic relevance. We combine 
single-cell microfluidic analysis with advanced computational modeling to study for the 
first time two common sources for cell-based therapies, human NSCs and MSCs. This 
methodology has the potential to logically inform cell source decisions for any clinical 
application.
Keywords: single-cell analysis, stem cell therapeutics, cellular heterogeneity
introdUCtion
The central nervous system is uniquely susceptible to injury and possesses a limited capacity for 
regeneration. Stem and progenitor cells are a promising therapeutic option as they potentially 
provide both cytokines and cellular substrate to promote tissue survival and regeneration. As such, 
cell therapies from a variety of sources [e.g., adult multipotent bone marrow (BM) and neural 
stem cells, and embryonic or induced pluripotent/neural progenitor cells] have been explored for 
a wide range of neurologic disorders, including Parkinson’s disease, stroke, and spinal cord injury 
(1, 2). Despite pre-clinical efficacy, there has been delayed clinical translation of this work as the 
mechanistic hypothesis has largely shifted from neural replacement to enhancing endogenous repair 
processes (3, 4). Recent increases in our understanding of the heterogeneity of stem and progenitor 
cell populations (5–8) provide a potential explanation for variable stem cell therapeutic efficacy, 
while also presenting an opportunity to tailor cell-based approaches to specific clinical applications.
Until recently, analytic approaches possessed inadequate resolution to study heterogeneous sam-
ples, such as stem and progenitor cells (9, 10), because the pooling of nucleic acids or proteins from 
hundreds of thousands of cells analyzed in aggregate is unable to account for cellular heterogeneity 
and potentially distinct cell subgroups. However, advances in microfluidic technology have enabled 
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massively parallel single-cell gene expression analyses that for the 
first time permit the high-resolution study of cell subpopulation 
heterogeneity and complex intercellular interactions (11–13). 
Leveraging this technology, we have refined a platform capable 
of performing high-resolution, high-throughput analyses of 
therapeutic and other cell sources (14–20). This approach 
combines single-cell transcriptional interrogation with advanced 
computational statistics to visualize cellular heterogeneity and 
identify distinct subpopulations for prospective enrichment. 
Characteristic cell signaling pathways can also be identified 
and compared, thus providing a logical approach to cell source-
application matching in the clinical setting.
MetHods
Human Bone Marrow Mesenchymal stem 
Cell isolation and Culture
Human bone marrow mesenchymal stem cells (hBM-MSCs) were 
isolated and cultured, as described previously (7, 21). Briefly, fol-
lowing written informed consent and approval of the ethical com-
mittee of the University Hospital Tübingen, Germany, BM aspirates 
from adult patients were obtained during orthopedic operations. 
BM mononuclear cells were isolated by density gradient centrifu-
gation, washed twice with phosphate buffered saline (PBS, Lonza, 
Walkersville, MD, USA), and seeded at a density of 1 × 105 cells/
cm2 in culture medium is composed of alpha minimum essential 
media (α-MEM, Lonza), 1%  penicillin– streptomycin (Lonza), 
and 10% pooled human blood group AB serum (ZKT Tübingen, 
Germany). Freshly obtained (P0) hBM-MSCs were cultured 
under standard conditions (37°C, 5% CO2), with non-adherent 
cells removed after 24 h. Medium was changed twice a week until 
cells reached subconfluency. hBM-MSCs were detached using 
Trypsin-EDTA (Lonza), counted using a CASY® cell counter 
(Roche, Basel, Switzerland), and cryopreserved for shipping to 
the United States. Upon thawing, hBM-MSCs from five separate 
donors were pooled and plated at a density of 1 × 104 cells/cm2 
for the next passage (P1). Cultured P1 hBM-MSCs were analyzed 
by microfluidic single-cell transcriptional profiling. Cultured P2 
hBM-MSCs were analyzed by flow cytometry.
Human neural stem Cell derivation  
and Culture
Human neural stem cells (hNSCs) were generated from human 
embryonic stem cells (hESCs), as previously described (22). 
Briefly, to generate hNSCs, dissociated hESCs [from the H9 
cell line (WiCell Research Institute, Madison, WI, USA)] were 
cultured in medium composed of Dulbecco’s modified Eagle’s 
medium (DMEM) and F12 nutrient (1:1 ratio), supplemented 
with glucose (0.6%), glutamine (2  mM), sodium bicarbonate 
(3  mM), and HEPES buffer (5  mM) [all from Sigma-Aldrich 
(St Louis, MO, USA) except glutamine (Invitrogen Life 
Technologies, Grand Island, NY, USA)]. A hormone and salt 
mixture (Sigma), composed of insulin (25 mg/ml), transferrin 
(100 mg/ml), progesterone (20 nM), putrescine (60 mM), and 
selenium chloride (30 nM), was used in place of serum, and the 
medium was also supplemented with epidermal growth factor 
(EGF, 20 ng/ml), basic fibroblast growth factor (bFGF, 10 ng/
ml), and leukemia inhibitory growth factor (LIF, 10  ng/ml). 
Cells were initially seeded at a density of 1 ×  105  cells/ml in 
Corning T75 (Invitrogen) culture flask, and after 5–7 days (prior 
to reaching confluency) the adherent culture was incubated in 
0.025% trypsin/0.01% EDTA (w/v) for 1 min, followed by the 
addition of trypsin inhibitor (Invitrogen) then gently triturated 
to achieve single cell suspension. The cells were then washed 
twice with fresh medium and reseeded in fresh growth factor-
containing media at 1 × 105 cells/ml. Subconfluent hNSCs were 
serially expanded in vitro prior to single cell and flow cytometric 
analyses.
Flow Cytometry and Microfluidic  
single-Cell Gene expression analysis
Single-cell reverse transcription and low cycle pre-amplification 
were performed, as previously described (15). Briefly, following 
12 h of serum starvation to synchronize cell cycles, cell suspen-
sions of hBM-MSCs and hNSCs were sorted as single cells into 
each well of a 96-well plate using a FACSAria flow cytometer 
(BD Biosciences, San Jose, CA, USA) into 6 μl of lysis buffer and 
SUPERase-In RNAse inhibitor (Applied Biosystems, Foster City, 
CA, USA). Live/dead gating was performed based on propidium 
iodide exclusion. Reverse transcription and low-cycle pre-
amplification was performed following addition of Superscript III 
reverse transcriptase enzyme (Invitrogen, Carlsbad, CA, USA), 
Cells Direct reaction mix (Invitrogen, Carlsbad, CA, USA), and 
target gene-specific TaqMan assay (primer/probe) sets (Applied 
Biosystems) (Tables  S1 and S2 in Supplementary Material) 
[20 min at 50°C, 2 min at 95°C, followed by a gene target-specific 
22-cycle pre-amplification (denature at 95°C for 15 min, anneal 
at 60°C for 4 min, each cycle)]. Exon-spanning primers were used 
where possible to avoid amplification of genomic background. 
Resultant single-cell cDNA was mixed with sample loading agent 
(Fluidigm, South San Francisco, CA, USA) and Universal PCR 
Master Mix (Applied Biosystems) and loaded into 96.96 Dynamic 
Array chips (Fluidigm) along with TaqMan assays (Tables S1 and 
S2 in Supplementary Material) and assay loading agent accord-
ing to the manufacturer’s instructions (Fluidigm). Products were 
analyzed on the BioMark reader system (Fluidigm) using a hot 
start protocol to minimize primer-dimer formation, 40 quantita-
tive PCR cycles were performed. Gene targets were selected after 
an exhaustive literature review relating to cell stemness, vasculo-
genesis, and neuronal regeneration for hBM-MSC analyses, and 
to cell stemness and lineage differentiation for hNSC analyses. 
Selected cell surface markers, housekeeping, and control genes 
were included in all microfluidic runs.
Flow cytometry was performed according to manufacturer’s 
instructions on a FACSAria flow cytometer (BD Biosciences). 
Briefly, hBM-MSCs and hNPCs cultured as above were incubated 
for 20  min in FACS buffer (PBS supplemented with 2% FBS) 
containing anti-human PE-conjugated TFRC [hBM-MSCs (BD 
Biosciences)], PE-conjugated PROM1 [hNSCs (Miltenyi Biotec, 
San Diego, CA, USA)] or PE-Cy7-conjugated CCR4 [hNScs 
(Biolegend, San Diego, CA, USA)] antibodies, respectively, and 
washed thoroughly prior to analysis.
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statistical analysis
Analysis of single-cell data was performed, as described previously 
(14, 15). The goal of this analysis was to identify cell subpopula-
tions with similar transcriptional signatures within putatively 
homogeneous populations (e.g., hBM-MSCs and hNSCs). Briefly, 
expression data from experimental chips were normalized rela-
tive to the median expression for each gene in the pooled sample 
and converted to base 2 logarithms. Absolute bounds (±5 cycle 
thresholds from the median, corresponding to 32-fold increases/
decreases in expression) were set, and non-expressers were 
assigned to this floor. Clustergrams were then generated using 
hierarchical clustering (with a “complete” linkage function and 
Euclidean distance metric) in order to facilitate data visualization 
via MATLAB (R2011b, MathWorks, Natick, MA, USA).
To detect overlapping patterns within the single-cell transcrip-
tional data, k-means clustering was employed using a standard 
Euclidean distance metric. Accordingly, each cell was assigned 
membership to a specific cluster as dictated by similarities in 
expression profiles (minimizing the within-cluster sum of square 
distances) in MATLAB. Optimally partitioned clusters were then 
sub-grouped using hierarchical clustering to facilitate visualization 
of data patterning (15). Partitional clustering of hNSCs for Figure S4 
in Supplementary Material was achieved through limiting our 
k-means algorithm to a subset of genes classified as “secreted fac-
tors,” whereas all 96 genes were utilized for purposes of gene-wise 
and intra-cluster cell-wise hierarchical clustering. In all single-cell 
data representations, gene-wise hierarchical clustering is visualized 
on the left, while cell-wise hierarchical clustering is on top.
Non-parametric, two-sample Kolmogorov–Smirnov (K–S) 
tests were used to identify those genes with expression patterns 
that differed significantly between population clusters and/or 
groups, following Bonferroni correction for multiple samples 
using a strict cutoff of p < 0.05. For subgroup comparisons, the 
empirical distribution of cells from each cluster was evaluated 
against that of the remaining cells in the experiment.
Ingenuity Pathway Analysis (IPA, Ingenuity Systems, Redwood 
City, CA, USA) was used to construct transcriptome networks 
based on genes that were significantly increased between hBM-
MSCs and hNSCs. For this analysis, the 68 common genes 
included in the corresponding single-cell analyses (rather than 
the entire transcriptome) was used as the reference set, in order 
to avoid biasing the associated enrichment calculations in IPA’s 
internal network generation algorithm.
resULts and disCUssion
In this work, we for the first time characterize subpopulations in 
hBM-MSCs and hESC-derived neural stem cells (hNSCs), utiliz-
ing this microfluidic single-cell approach, to gain insights into the 
optimal clinical applications of these cell sources. Interestingly, 
significant heterogeneity was observed in both cell types 
(Figures 1 and 2A,B). Moreover, automated partitional clustering 
(i.e., cell groupings based on similarities in gene expression; see 
“Statistical Analysis” in Section “Methods” for complete descrip-
tion) of these data identified distinct transcriptionally defined 
cellular subpopulations of clinical relevance (Figures  1 and 
2C,D), with gene expression profiles suggestive of a potentially 
beneficial effect of subfractionation. In particular, a distinct 
subpopulation of hBM-MSCs displayed enhanced expression of 
genes encoding secreted factors associated with neuronal growth, 
differentiation, and survival (such as LIF, CCL2, BMP4, NGF, 
and FGF2) (Figures 1C–E), making it particularly appealing for 
neuroregenerative cell therapy applications, such as following 
ischemic or traumatic insult. Conversely, hNSCs possessed two 
cell subpopulations with gene profiles suggestive of differential 
lineage commitment [i.e., pre-astrocytes/glial cells defined by 
SLC1A3, APOE, and GPC6 expression (23–25) and pre-neurons 
characterized by SPP1 and PAX6 (26, 27)] (Figures  2C–F), 
further supporting the concept of functional cell heterogeneity 
within precursor cell populations and highlighting the potential 
for targeted purification based on clinical need. Importantly, the 
subpopulations of interest in both hBM-MSCs and hNSCs were 
co-defined by expression of cell surface marker genes (Figures S1 
and S2 in Supplementary Material), which may enable their 
prospective isolation for experimental or therapeutic application.
Despite likely differences in mechanism of action, progenitor 
cells from disparate sources have been tested in similar neurore-
generative settings. To gain insight into the signaling differences 
across cell types that may guide their clinical application, we 
directly compared the single-cell transcriptional profiles and 
activated gene networks of hBM-MSCs and hNSCs (Figure 3). 
Consistent with the developmentally distinct origins of these 
cells (i.e., adult versus embryonic derived), significant differences 
were observed across cell types in this analysis, although each 
displayed a pro-regenerative profile. Specifically, hBM-MSCs 
possessed a pro-vascular phenotype (defined in part by expres-
sion of CXCL12, PDGFRA, VEGFA, and HGF) (Figures 3B,D), 
while hNSCs featured a more stem-like and pro-neuronal 
profile (including upregulation of BMP2, NANOG, and GPC6) 
(Figures  3C,E). Subclustering of these combined single-cell 
data suggests that these cell entities would function differently 
following injury, with cell origin being the dominant driver of 
cluster formation. In fact, there was an absence of common, 
transcriptionally defined cellular subpopulations across groups 
(Figure S3 in Supplementary Material). Importantly, the iden-
tification of such cell-specific signaling suggests a potential 
synergy of mixed cell therapies for clinical applications. For 
example, LIF expression in hBM-MSCs (a cytokine that pro-
motes neuronal precursor differentiation) (28) could be coupled 
with LIF receptor (LIFR) expression in hNSCs to simultaneously 
promote neovascularization and site-specific differentiation of 
applied neural precursors.
These data demonstrate the utility of single-cell analysis for 
the characterization and potential improvement of cell-based 
therapeutics for neurodegenerative and other diseases. Moreover, 
the heterogeneity of the cell populations studied herein, only 
visible with this or similar resolution platforms, highlights the 
potential for tailoring cell therapies based on clinical need. 
Specifically relating to stroke therapies, the recently proven effi-
cacy of endovascular thrombectomy for large vessel occlusions 
(29–32) provides a currently unutilized opportunity to deliver 
neuroprotective and regenerative cells directly to ischemic 
brain tissue upon revascularization. In this scenario, single or 
combined cell subpopulations with desired cell profiles could be 
FiGUre 1 | single-cell transcriptional analysis of hBM-MsCs. (a) Hierarchical clustering of cells (gene-wise clustering on left, cell-wise clustering on top). 
Gene expression presented as fold change from median (yellow, high expression, 32-fold above median to blue, low expression, 32-fold below median). (B) Whisker 
plots presenting raw qPCR cycle threshold values for each gene across all cells. Individual dots represent single gene/cell qPCRs, with increased cycle threshold 
values corresponding to decreased mRNA content. Cycle threshold values of 40 represent failed amplifications. (C) K-means clustering of hBM-MSCs (k = 4). (d,e) 
hBM-MSC cluster pie chart representing the fraction of cells comprising each cluster and selected cluster 1 defining genes determined via Kolmogorov–Smirnov 
testing.
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FiGUre 2 | single-cell transcriptional analysis of hnsCs. (a) Hierarchical clustering, whisker plots (B), and K-means clustering (C) of hNSCs (k = 4). (d–F) 
hNSC cluster pie chart representing the fraction of cells comprising each cluster and selected cluster 1 and 2 defining genes determined via Kolmogorov–Smirnov 
testing.
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FiGUre 3 | Comparative single-cell analysis of hBM-MsCs and hnsCs. (a) Hierarchical clustering of cells from hBM-MSCs (left) and hNSCs (right) with gene 
expression presented as fold change from median. (B,C) Selected differentially expressed genes relating to cell stemness and pro-vascular/neuronal survival 
between hBM-MSCs and hNSCs identified using non-parametric two-sample Kolmogorov–Smirnov testing, illustrated with median-centered Gaussian curve fits [(B) 
genes upregulated in hBM-MSCs; (C) genes upregulated in hNSCs]. The left bar for each panel represents the fraction of qPCRs that failed to amplify in each group. 
(d,e) Top scoring Ingenuity Pathway Analysis (IPA)-constructed transcriptome networks based on genes significantly increased in hBM-MSCs (d) and hNSCs (e), 
respectively. Significant “seed” genes are colored in blue or red to distinguish them from the remaining “inferred” entities in the network.
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prospectively isolated prior to application. Although unbiased 
partitional clustering was used herein to identify physiological 
cell subpopulations, an alternative analytical approach with 
restricted clustering based on desired gene expression (such as 
secreted cytokines and growth factors) could be employed to 
prospectively identify groups of cells with a specific profile of 
interest (Figure S4 in Supplementary Material). As such, we envi-
sion that a similar methodology could be applied to any cell type 
to logically inform cell source decisions and improve cell-based 
therapies for neurologic pathologies.
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FiGUre s1 | List of hBM-MsC and hnsC cluster defining genes 
determined via Kolmogorov–smirnov testing from Figures 1 and 2. Bold 
genes encode cell surface markers.
FiGUre s2 | (a) Flow cytometric analysis of hBM-MSCs demonstrating 
differential expression of the cell surface protein TFRC, a potential marker for 
prospective hBM-MSC Cluster 1 isolation. (B) Flow cytometric analysis of hNSCs 
demonstrating differential expression of the cell surface proteins PROM1 and 
CCR4 (hi/low gating), potential markers for hNSC Cluster 1 and 2 enrichment, 
respectively. Left plots negative controls and right plots stained cells.
FiGUre s3 | (a) Hierarchical clustering of cells from hBM-MSCs (left) and 
hNSCs (right) with gene expression presented as fold change from median 
(as presented in Figure 3). (B) K-means clustering of hBM-MSCs and hNSCs 
(k = 1–5), with pie charts representing the fraction of cells comprising each 
cluster [hBM-MSC (blue), hNSC (red)].
FiGUre s4 | (a,B) Single-cell transcriptional analysis of hNSCs clustered on 
genes for coding for secreted proteins (k = 4) (a). (B) List of secreted protein 
gene names with percent of cellular expression. (C) Pie chart representing the 
fraction of hNSCs comprising each cluster, with associated surface marker 
genes from the highest expressing cluster (cluster 1) (d), which could potentially 
enable subpopulation enrichment.
taBLe s1 | Gene names and assay ids for microfluidic single-cell gene 
expression analysis of hBM-MsCs. Genes specifically relating to stemness, 
neuronal survival, and vasculogenesis were chosen, in addition to selected 
control, cell-cycle, and surface marker-related probes.
taBLe s2 | Gene names and assay ids for microfluidic single-cell gene 
expression analysis of hnsCs. Genes specifically relating to stemness, 
neuronal survival, and vasculogenesis were chosen, in addition to selected 
control, cell-cycle, and surface marker-related probes.
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